Synolis is a viscosupplement designed for a flexible treatment for all patients suffering from osteoarthritis by mimicking the properties of a young and healthy synovial fluid. Synolis is a gel composed of 2% highly purified non-crosslinked HA with 4% of Sorbitol.
Viscosupplementation (VS) or intra-articular injections of Synolis is a symptomatic treatment of ostheoarthritis reducing pain and restoring mobility in the affected synovial joint. Therefore, Synolis reduces local pain and discomfort caused by symptomatic OA and improves mobility of the synovial joints.
In healthy joints, hyaluronic acid (HA or NaHA) in the synovial fluid is constantly broken down and replaced in the body. In osteoarthritis, breakdown occurs by oxidants like reactive oxygen species (ROS) or by hyaluronidases. This process is faster than the replacement, which results in a less viscous synovial fluid that does not function properly.
The main interest of Sorbitol is to protect NaHA during shelf life and after injection against premature degradation because of surrounding inflammation and free radicals. Even though the hyaluronic acid is not crosslinked, Synolis is a stable gel because of the strong affinity between Sorbitol and the hyaluronic acid. Due to the high amount of hydrogen bonds created by the mix of NaHA and Sorbitol, the gel is not immediately dissolved like other linear NaHA.
Sorbitol is known to be a very performing antioxidant in the polyol family more than mannitol or glycerol. Sorbitol protects the hyaluronic acid against premature degradation. The Sorbitol’s hygroscopic effect strengthens the hydrating power of the hyaluronic acid. In preserving viscosity and elasticity the Sorbitol allows the hyaluronic acid a better performance such as high lubrication, restoration of the viscoelastic properties of a healthy synovial fluid and a better shock absorbance.
The costs for a treatment with Synolis vary on the indication and injection regimen.
Please consult with your medical professional.
The treatment must be adapted depending on radiological and medical diagnosis. Available clinical data have demonstrated performance of different injection regimen based on the severity of osteoarthritis. The treating physician will discuss the different treatment options during the consultation with you.
Synolis has been appreciated by patients and users in over 50 countries for many years. Aptissen SA, the manufacturer of Synolis, based in Switzerland, places a great focus on the highest quality. The mode of action and the effects of a Synolis treatment are the subject of numerous clinical studies and publications. Please click here for an excerpt of clinical papers and discover what patients say about Synolis here.
Synolis treatment is performed exclusively by medical professionals. In general, local anesthesia is not necessary.
Synolis is indicated to reduce pain and improve mobility due to degenerative changes in the knee and other synovial joints linked to osteoarthritis.
Clinical studies have shown a reduction in pain and an improvement in mobility within a few days of treatment.
Hyaluronic acid is the most important component of the synovial fluid and acts as a joint lubricant and shock absorber. Synovial fluid is found in the joint space and protects the cartilage and bone. The injected hyaluronic acid replenishes the synovial fluid and replaces modified hyaluronic acid, helping to lubricate the joint and ease symptoms. Synolis consists of 2% non-crosslinked non-animal Hyaluronic acid.
During the design phase of Synolis, we were looking for a strong antioxidant to protect the hyaluronic acid against premature degradation. Sorbitol is known to be a very performing antioxidant in the polyol family more than mannitol or glycerol. The Sorbitol’s hygroscopic effect strengthens the hydrating power of the hyaluronic acid. In preserving viscosity and elasticity Sorbitol allows the hyaluronic acid a better performance such as high lubrication, restoration of the viscoelastic properties of a healthy synovial fluid and a better shock absorbance.
Sorbitol benefits from very long and positive medical tracking records. It can be found naturally in many fresh fruits and berries but also it can be produced by hydrogenation of glucose in animal and human bodies. Synolis contains 4% Sorbitol.
Synolis treatments are performed exclusively by medical professionals e.g. orthopedists, rheumatologists, sports physicians. Prior to treatment, the practitioner of your choice will perform a basic diagnosis and present an individual treatment concept. Please visit Find a treatment center to get in touch with our providers.
Synolis is available in more than 50 countries worldwide. Please visit Find a treatment center to get in touch with one of our providers.
Osteoarthritis is a chronic joint disease that is linked to cartilage breakdown and can occur in almost any joint in the body (mostly the ones that bear weight, such as the knee and hip). The elderly are not the only ones affected by osteoarthritis. Although it is more common in elderly people, athletes and younger individuals are also susceptible to suffer of osteoarthritis.
Possible side effects exist and must be described to the patient before treatment. Slight bleeding may occur during the injection, although it stops spontaneously as soon as the injection is completed. In occasional cases one or more of the following reactions may occur either immediately or as a delayed reaction. It can be temporary local pain, oedema, and/or joint effusion. These reactions usually heal within few days. If these symptoms persist for over a week, or if any other side effects occur, the patient must inform the doctor. The doctor may prescribe appropriate treatment for these undesirable effects. Other possible typical side effects of viscosupplement injections include inflammation, redness, swelling, skin irritation, allergic and tissue reaction.
Please consult with your medical provider if you are eligible for a treatment with Synolis.
Synolis was designed to provide the exact properties of a young and healthy joint fluid.
The function of the synovial fluid is to absorb shock during movement and to provide lubrication at rest. For this reason, the state of the synovial fluid must be able to adapt: elastic in motion, viscous at rest. The transition from viscous to elastic occurs at a frequency of 0.4Hz of a young and healthy synovial fluid. Arthritic joint fluid can no longer adapt to the requirements and the typical symptoms such as pain and limited mobility arise.
Osteoarthritis is a chronic joint disease that is linked to cartilage breakdown and can occur in almost any joint in the body (mostly the ones that bear weight, such as the knee and hip). The elderly are not the only ones affected by osteoarthritis. Although it is more common in older people, athletes and younger individuals are also susceptible to suffer of osteoarthritis.
You might experience joint aches, pain, stiffness or even joint swelling. The symptoms of osteoarthritis most often develop gradually with time; although there is no cure, there are different treatments available to ease your pain and restore your mobility.
Sorbitol passes through the synovial membrane to the blood stream, unless retained by HA, and is metabolized by the liver as fructose that is highly tolerated by diabetic patients. Then, it is eliminated by hepatic sorbitol dehydrogenase.
There are numerous viscosupplement products available worldwide. These vary greatly in composition, volume and ingredients. Unfortunately, clinical data is limited for many available products. The ingredients in Synolis are of non-animal origin and therefore carry no risk of allergic reactions. The composition of Synolis with 2% non-cross-linked hyaluronic acid and 4% sorbitol lies in its ability to mimic a gel with the exact properties of a young and healthy synovial fluid. Synolis is the subject of many clinical studies
Discover what patients say about Synolis here.